Eli Lilly Acquires AtaiBeckley for Up to $3.8 Billion
Published on Β· Source: cnbc.com
AI Summary
Summarized by AI from the source belowEli Lilly has announced its acquisition of AtaiBeckley for up to $3.8 billion, indicating a shift in Big Pharma's approach to psychedelic drugs for mental health. This acquisition follows positive clinical trial results for psychedelics, including Atai's BPL-003, a synthetic form of 5-MeO-DMT, currently in Phase 3 trials. The FDA has granted BPL-003 Breakthrough Therapy Designation, expediting its development for treatment-resistant depression, which affects around four million Americans. Analysts estimate that success in Phase 3 trials could open up a $1-2 billion market opportunity in this sector, signaling potential growth for investors interested in biotech innovations in mental health treatments.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Eli Lilly and Company (LLY)
Eli Lilly is a major pharmaceutical company known for diabetes and obesity treatments and a broad drug pipeline.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier LLY news
- Eli Lilly Stock Surge Driven by New Factors, Not Weight Loss
- Lilly Nears Acquisition Deal for AtaiBeckley Drugmaker
- IBB Up 51% Yearly; Eli Lilly (LLY) Completes Four Acquisitions
- Premarket Moves: Key Stocks Including AAPL, PEP, CRM, and LLY
- Lilly (LLY) to Present Alzheimer's Research at London Conference
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
